Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Israel to offer fourth COVID-19 vaccine dose in bid to outpace Omicron

CoronavirusDec 22, 2021 02:01PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A elderly woman receives a booster shot of her vaccination against the coronavirus disease (COVID-19) at an assisted living facility, in Netanya, Israel January 19, 2021. REUTERS/Ronen Zvulun

JERUSALEM (Reuters) -Israel is to offer a fourth dose of a COVID-19 vaccine to people older than 60 or with compromised immune systems, and to health workers, as part of a drive to ramp up the shots and outpace the spread of the Omicron variant of the coronavirus.

A Health Ministry expert panel - whose findings have yet to be implemented - recommended on Tuesday that those eligible should receive the fourth shot at least four months after receiving their third.

Prime Minister Naftali Bennett, who has sought to drum up higher Israeli turnout for vaccines, welcomed the panel's statement as "great news that will help us overcome the Omicron wave that is spreading around the world".

The panel further recommended that the time between the second and third shots be reduced to three months from five.

Such measures would be "part of the preparation for the fifth wave" of the pandemic, said the panel's statement, which did not present specific data behind the recommendations.

"We are seeing a waning of protection against Omicron infection. This wave is growing in surprisingly high numbers... More than 80% of the panel supported this measure," Arnon Shahar, a doctor on the expert panel, told Israel's Army Radio.

The recommendations must be approved by the Health Ministry director-general, Nachman Ash. The ministry did not say when that might happen.

TURNOUT PLATEAU

After a world-beating vaccine rollout, Israel has seen turnout for the shots plateau. Around 62% of its 9.4 million population have received two doses, the ministry said.

The Bennett government moved quickly against Omicron, barring foreigners from entering Israel on Nov 25 and expanding a list of high-risk countries to which its citizens should not travel to include the United States this week.

On Tuesday, an Israeli hospital reported the country's first known death of a patient with Omicron, before amending the statement to say a final laboratory investigation had determined he was infected with the Delta variant. Soroka Medical Center said the man, in his 60s and with serious pre-existing conditions, died on Monday, two weeks after he was admitted to a COVID-19 ward.

The Health Ministry said there were at least 340 known cases of Omicron in Israel as of Tuesday.

Bennett's office also approved reducing office attendance by 50% for public sector employees to encourage more remote work. Defence Minister Benny Gantz ordered the military’s Homefront Command to prepare for the eventuality of 5,000 new cases per day, his office said.

Israel has been deploying shots developed by Pfizer-BioNTech as part of its vaccination campaign, which was one of the world's fastest at the start of this year.

Asked about Israel's plan, a spokeswoman for Pfizer (NYSE:PFE) said the company plans to assess the immune system response and efficacy of additional doses of its current formulation and an Omicron-specific one in a clinical setting.

She did not give a timeframe.

The U.S. drugmaker will also evaluate data from Israel's rollout of fourth doses, she said.

Early lab work has shown that vaccines' ability to neutralise the virus wanes with time after the third dose, a professor of biology at Temple University in Philadelphia, Enrico Bucci, said.

Israel's plan may be a test of that in a real-world setting, he said.

Israel to offer fourth COVID-19 vaccine dose in bid to outpace Omicron
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (5)
Bernard Devlin
Bernard Devlin Dec 22, 2021 8:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What's the point of a fourth Jab when the previous 3 did not work. There have been no clinical trials on the efficacy of people being injected with 3, let alone 4 of these Jabs. What the heck is going on?
Anthony Cloud
Anthony Cloud Dec 22, 2021 6:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is laughable
neang aee 냥에
neang aee 냥에 Dec 22, 2021 2:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
with no use
Edward Chong
Edward Chong Dec 21, 2021 11:58PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
only they will do such things.
Ankit Jain
Ankit Jain Dec 21, 2021 10:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this is a never ending process it seem
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email